Pfizer Provides Update On GLP-1-RA Clinical Development Program For Adults With Obesity And Type 2 Diabetes Mellitus
Portfolio Pulse from Benzinga Newsdesk
Pfizer is advancing its oral GLP-1-RA candidate danuglipron towards late-stage development for the treatment of obesity and type 2 diabetes mellitus (T2DM). The ongoing Phase 2b study in obesity is fully enrolled, with over 1,400 participants. Pfizer will discontinue its second GLP-1-RA candidate, lotiglipron.
June 26, 2023 | 10:53 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pfizer advances danuglipron, an oral GLP-1-RA candidate for obesity and T2DM treatment, towards late-stage development. The company will discontinue its second candidate, lotiglipron.
Pfizer's advancement of danuglipron towards late-stage development indicates positive progress in the treatment of obesity and T2DM. This could potentially lead to increased revenues and a positive impact on the stock price. The discontinuation of lotiglipron may be seen as a strategic move to focus on the more promising candidate.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100